High relapse rate seen at week 72 for patients treated with R1626 combination therapy

Authors


  • Potential conflict of interest: Dr. Pockros is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche and Vertex. He is a consultant for, advises, and received grants from Pfizer. Dr. Godofsky is a consultant for, is on the speakers' bureau of and received grants from Roche. Dr. Everson is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Ghalib is on the speakers' bureau of and received grants from Roche, Schering-Plough, Idenix, and Three River. Dr. Harrison advises, is on the speakers' bureau of, and received grants from Roche and Schering-Plough. Dr. Nyberg is on the speakers' bureau of and received grants from Schering-Plough. She also received grants from Roche, Vertex, Idenix, and Human Genome Sciences. Dr. Shiffman is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. He is a consultant for and received grants from Vertex. He is on the speakers' bureau of and received grants from Schering-Plough.

No abstract is available for this article.

Ancillary